Scientists at the Genome Institute at Washington University School of Medicine in St. Louis have identified nearly all genetic mutations associated with acute myeloid leukemia (AML). According to Dr. Timothy Ley, associate director for cancer genomics at the Genome Institute, this genetic discovery "can help us begin to understand which patients need more aggressive treatment right up front, and which can be treated effectively with standard chemotherapy." These findings could lead to improved treatment for AML, a cancer that is expected to afflict 15,000 Americans this year.
For more information on this study, click here.
Study source: Steensma, D. The beginning of the end of the beginning in cancer genomics. New Engl J Med. 2013 May 1 [online first]
No comments:
Post a Comment